Core Viewpoint - Itochu Asia plans to reduce its stake in Sheng Tai Group by up to 3% of the total share capital through both centralized bidding and block trading methods, following a notification issued on September 1, 2025 [1] Group 1: Shareholding and Reduction Plan - As of the announcement date, Itochu Asia holds 116,680,000 shares in Sheng Tai Group, representing 21.00% of the total share capital [1] - The reduction plan allows for a maximum of 5,555,600 shares (1% of total share capital) to be sold through centralized bidding within three months after the announcement, and an additional 11,111,200 shares (2% of total share capital) through block trading [1] Group 2: Company Background and Financials - Sheng Tai Group was listed on the Shanghai Stock Exchange on October 27, 2021, with an initial issuance of 55.56 million shares at a price of 9.97 yuan per share [2] - The total funds raised from the initial public offering amounted to 554 million yuan, with a net amount of 463 million yuan after expenses [2] - The company has also issued convertible bonds in 2022, raising a total of 701.18 million yuan, with a net amount of approximately 683.85 million yuan after deducting issuance costs [3][4]

Group 1 - The core point of the news is that Aojie Technology (688220.SH) announced a share reduction plan by its shareholder Alibaba (China) Network Technology Co., Ltd., intending to reduce up to 12,549,025 shares, accounting for no more than 3% of the total share capital within three months after the announcement [1] - As of the announcement date, Alibaba Network directly holds 64,557,440 shares, representing 15.4333% of the total share capital, with these shares originating from the company's pre-IPO holdings [1] - Aojie Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 14, 2022, with an initial issuance of 41,830,089 shares at a price of 164.54 yuan per share, but the stock has been trading below its IPO price since listing [1] Group 2 - The total amount raised from Aojie Technology's IPO was 6.883 billion yuan, with a net amount of 6.546 billion yuan after deducting issuance costs, exceeding the original plan by 4.166 billion yuan [2] - The funds raised are intended for various projects, including new communication chip design, smart IPC chip design, high-precision navigation solutions, research center construction, and working capital [2] - The total issuance costs for the IPO were 337 million yuan, with underwriting fees accounting for 310 million yuan [3]

Group 1 - The core point of the article highlights that Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a decline in stock price, closing at 14.63 yuan with a drop of 3.81%, resulting in a total market capitalization of 5.852 billion yuan [1] - The company went public on March 20, 2023, on the Shenzhen Stock Exchange's ChiNext board, issuing 47.2572 million shares at an initial price of 50.00 yuan per share [1] - On its first trading day, the stock reached a peak price of 45 yuan but has since experienced a downward trend [1] Group 2 - Hongyuan Pharmaceutical raised a total of 236.286 million yuan through its initial public offering, with a net amount of 219.58437 million yuan after deducting issuance costs, which exceeded the original plan by 154.51137 million yuan [1] - The company had initially planned to raise 65.073 million yuan for projects including a research center, multifunctional testing workshop, antiviral raw materials and intermediates project, and a high-end formulation workshop with an annual production capacity of 2.5 billion tablets [1] - The total issuance costs amounted to 16.70163 million yuan, with underwriting and sponsorship fees accounting for 13.93196 million yuan [1]

Core Viewpoint - China Chengda Engineering Co., Ltd. plans to reduce its stake in Huashu Co., Ltd. by up to 10 million shares, representing 0.28% of the total share capital, within a 90-day period [1] Shareholder Reduction Plan - China Chengda intends to sell no more than 10,000,000 shares, which is capped at 1% of the total shares within any consecutive 90 days [1] - As of the announcement date, China Chengda holds 180,000,000 shares, accounting for 5.01% of Huashu's total share capital [1] Shareholding Structure - The top shareholders include Huai Bei Mining Group with 1,740,036,832 shares (48.41%), Anhui Wantou Industrial Investment Co., Ltd. with 359,473,816 shares (10.00%), and China Chengda Engineering Co., Ltd. with 180,000,000 shares (5.01%) [2] - Huashu Co., Ltd. was listed on the Shanghai Stock Exchange on November 26, 2021, with an initial public offering of 386 million shares at a price of 3.94 yuan per share [2] Fundraising and Financials - Huashu raised a total of 1.521 billion yuan through its initial public offering, with a net amount of 1.402 billion yuan after deducting issuance costs [3] - The company plans to use the raised funds for various projects, including energy efficiency upgrades and production expansions [3] - The total fundraising from two rounds amounts to 1.721 billion yuan [4]

中国经济网北京8月21日讯中触媒(688267.SH)昨日晚间披露《持股5%以上股东减持股份计划公告》。 王婧为中触媒直接持股5%以上股东，无一致行动人。王婧上市以来未减持股份。2025年半年报显示， 王婧为公司第三大股东。 本次减持计划系股东根据自身资金需求进行的减持，不会对公司治理结构及持续经营情况产生重大影 响。减持计划实施不会导致上市公司控制权发生变更。 中触媒于2022年2月16日在上交所科创板上市，发行价格为41.90元/股。中触媒上市发行数量为4405.00 万股，保荐机构(主承销商)为申万宏源证券（000562）承销保荐有限责任公司，保荐代表人为黄霖、刘 国库。目的该股处于破发状态。 中触媒发行募集资金总额为18.46亿元，扣除发行费用后，募集资金净额为16.91亿元。中触媒最终募集 资金净额比原计划多9.07亿元。中触媒于2022年2月11日披露的招股说明书显示，公司拟募集资金7.84亿 元，分别用于"环保新材料及中间体项目""特种分子筛、环保催化剂、汽车尾气净化催化剂产业化项 目"。 中触媒公开发行新股的发行费用合计1.55亿元(不含增值税金额)，其中保荐机构申万宏源证券承销保荐 有限责任 ...

Group 1 - The stock of Frontline Bio (688221.SH) closed at 18.25 yuan, with a decline of 4.4%, currently in a state of breaking issue [1] - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital after issuance, at a price of 20.50 yuan per share [1][2] - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan, intended for various clinical research projects and working capital [2][4] Group 2 - The highest stock price of Frontline Bio on the listing day was 35.53 yuan, marking the peak since its listing [2] - The underwriting and sponsorship fees for the initial public offering amounted to 12.689 million yuan, with the underwriting and sponsorship fee being 11.613 million yuan [2] - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3]

Core Viewpoint - Wankai New Materials (301216.SZ) is currently experiencing a decline in stock price, closing at 15.94 yuan with a drop of 3.57%, indicating a state of being below its initial public offering price [1] Group 1: Initial Public Offering and Financials - Wankai New Materials was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on March 29, 2022, with an initial public offering of 85.85 million shares at a price of 35.68 yuan per share [1] - The total funds raised from the IPO amounted to 3.063 billion yuan, with a net amount of 2.915 billion yuan after expenses, exceeding the planned fundraising by 1.411 billion yuan [1] - The company intended to use the raised funds for projects including a 1.2 million ton food-grade PET polymer material project (Phase II), a multifunctional green and environmentally friendly polymer material project, and to supplement working capital [1] Group 2: Subsequent Financial Activities - The total issuance costs for the IPO were 148 million yuan, with underwriting and sponsorship fees accounting for 123 million yuan [2] - On May 31, 2023, Wankai New Materials announced a dividend plan, distributing 3 yuan (pre-tax) for every 10 shares and a bonus issue of 5 shares [2] - The company plans to issue convertible bonds with a total fundraising amount not exceeding 2.7 billion yuan, which will be used for a 1.2 million ton MEG project and to supplement working capital, with the listing date set for September 5, 2024 [2][3]

中国经济网北京8月18日讯ST中装（002822）(002822.SZ)今日收报3.52元，跌幅1.95%。该股目前处于 破发状态。 ST中装于2016年11月29日在深圳证券交易所上市，公开发行股票7,500万股，发行价格为10.23元/股，保 荐机构(主承销商)为国海证券股份有限公司，保荐代表人为陈贤德、关建宇。 ST中装首次公开发行股票募集资金总额为76,725.00万元，募集资金净额为67,603.20万元。ST中装最终 募集资金净额比原计划少31.77万元。ST中装招股说明书显示，该公司拟募集资金67,634.97亿元，分别 用于部品部件工厂化生产项目、营销中心建设项目、设计研发中心建设项目、信息化系统建设项目、补 充公司流动资金。 ST中装首次公开发行股票的发行费用总额为9,121.80万元，其中，保荐及承销费7,100万元。 据ST中装年度募集资金使用情况专项说明，公司2019年公开发行可转换公司债券的募集资金情况为， 经中国证券监督管理委员会"证监许可[2018]1911号"文核准，中装建设公司获准公开发行面值总额为人 民币525,000,000.00元可转换公司债券，期限6年，募集资金总额为 ...

Core Viewpoint - The specific shareholder, Hangzhou Guangfeng Qiwo Equity Investment Partnership, plans to reduce its holdings in Heshun Technology by up to 655,300 shares, representing 0.8191% of the total share capital, over a three-month period starting from September 4, 2025 [1][2]. Group 1 - The reduction will occur through centralized bidding or block trading, with a limit of 655,300 shares within any continuous 90-day period [1]. - As of the announcement date, Guangfeng Qiwo holds 655,300 shares, making it the fifth largest shareholder of Heshun Technology [2]. - The implementation of this reduction plan will not lead to a change in the company's control or affect its ongoing operations [3]. Group 2 - Heshun Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on March 23, 2022, with an initial public offering of 20 million shares at a price of 56.69 yuan per share [3]. - The company raised a total of 1.134 billion yuan, with a net amount of 1.018 billion yuan after expenses, exceeding the original fundraising plan by 403 million yuan [4]. - The funds raised are intended for the construction of a polyester film production base, a research and development center, and to supplement working capital [4].

为满足自身资金需求，范俊拟通过集中竞价方式减持其持有的希荻微股份数量合计不超过3,000,000股， 占希荻微目前总股本的比例合计不超过0.73%，减持期间为减持股份计划公告披露15个交易日后的3个 月内。减持价格按照市场价格确定，若希荻微在上述减持计划实施期间发生派发红利、送红股、转增股 本、增发新股或配股等股本除权、除息事项的，则上述减持计划将作相应调整。 截至减持股份计划公告披露日，范俊持有希荻微股份13,049,225股，占希荻微目前总股本的3.18%。上 述股份均来源于希荻微首次公开发行前取得的股份，已全部解除限售。 根据希荻微披露的2024年年度报告，该公司无控股股东，实际控制人为戴祖渝、陶海(TAOHAI)、唐 娅。戴祖渝，中国国籍；陶海(TAOHAI)，美国国籍；唐娅，中国国籍。 中国经济网北京8月13日讯希荻微(688173.SH)于8月11日晚间发布公告称，公司于2025年8月11日收到公 司董事、副总经理、核心技术人员范俊出具的《关于希荻微电子集团股份有限公司股份减持计划的告知 函》。 希荻微于2022年1月21日在上交所科创板上市，公开发行股票数量为4001万股，发行价格为33.57元 ...